Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.42 |
| ▸ | CD38 | P28907 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439811 | 0.93 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5177042 | 0.91 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5177681 | 0.91 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5177877 | 0.89 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5431516 | 0.83 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5177207 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5175712 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5176723 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5439817 | 0.82 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 | |
| SCHEMBL5178535 | 0.81 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287726-A1 | 5-Substituted 1H-Pyrrolo [3,2-B] Pyridines | ALTANA PHARMA AG (DE) | 2007-12-13 | — | — | US | disclosed |
| EP-1776361-A1 | 5-SUBSTITUTED 1H-PYRROLOÝ3,2-B¨PYRIDINES | Altana Pharma AG (DE) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006013195-A1 | 5-SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINES | ALTANA PHARMA AG (DE) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287726-A1 | 5-Substituted 1H-Pyrrolo [3,2-B] Pyridines | GIPR, VIP, PGC | CYP3A4 367/4885CYP2C9 552/4885CYP2C19 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.